Literature DB >> 7692810

Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia.

T Klockgether1, L Turski.   

Abstract

Increased glutamatergic transmission in the basal ganglia is implicated in the pathophysiology of Parkinson's disease. However, the mechanisms by which activation of glutamate receptors produce parkinsonism are unknown. Therefore, we examined whether the glutamate agonists N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), kainate, and trans-(+/-)-1-amino-1,3-cyclopentanedicarboxylate produce parkinsonism in rats after microapplication into different subregions of the basal ganglia. Electromyographic activity was used as a measure of parkinsonian rigidity. We found that in the rostral striatum, excitation mediated by NMDA but not by non-NMDA receptors led to parkinsonism. In the substantia nigra pars reticulata, internal pallidal segment/entopeduncular nucleus, and subthalamic nucleus, activation of AMPA/kainate and metabotropic receptors but not of NMDA receptors led to parkinsonian rigidity. Rigidity occurred also in animals bearing ibotenate-induced lesions of the posterior part of the striatum and of the external pallidal segment, but not in animals with lesions of the anterior striatum, subthalamic nucleus, internal pallidal segment/entopeduncular nucleus, or substantia nigra pars reticulata. These observations suggest that the activation of glutamate receptor subtypes in the basal ganglia may be differentially involved in the expression of parkinsonian symptoms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692810     DOI: 10.1002/ana.410340413

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  Neuronal death enhanced by N-methyl-D-aspartate antagonists.

Authors:  C Ikonomidou; V Stefovska; L Turski
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

2.  A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.

Authors:  J E Nash; J M Brotchie
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

3.  Effect of nicotine on the level of extracellular amino acids in the hippocampus of rat.

Authors:  E Toth
Journal:  Neurochem Res       Date:  1996-08       Impact factor: 3.996

4.  Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies.

Authors:  J Kornhuber; C G Parsons; S Hartmann; W Retz; S Kamolz; J Thome; P Riederer
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 5.  Drug treatment of Parkinson's disease in the 1990s. Achievements and future possibilities.

Authors:  A J Hughes
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

6.  Antiparkinsonian effect of flupirtine in monoamine-depleted rats.

Authors:  M Schwarz; M Nolden-Koch; J Purr; G Pergande; F Block
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 7.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

8.  An analytical flow injection system to measure glutamate in microdialysis samples based on an enzymatic reaction and electrochemical detection.

Authors:  Alberto Morales-Villagrán; Cuauhtemoc Sandoval-Salazar; Laura Medina-Ceja
Journal:  Neurochem Res       Date:  2008-04-22       Impact factor: 3.996

Review 9.  Manganese neurotoxicity and the role of reactive oxygen species.

Authors:  Ebany J Martinez-Finley; Claire E Gavin; Michael Aschner; Thomas E Gunter
Journal:  Free Radic Biol Med       Date:  2013-02-08       Impact factor: 7.376

10.  Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms.

Authors:  C B Carroll; V Holloway; J M Brotchie; I J Mitchell
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.